Long-term survival after complete resection of non-small-cell lung cancer in patients with interstitial lung disease

Sekihara, Keigo; Aokage, Keiju; Oki, Tomonari; Omori, Tomokazu; Katsumata, Shinya; Ueda, Toshihisa; Miyoshi, Tomohiro; Goto, Masaki; Nakasone, Shoko; Ichikawa, Tomohiro; Hishida, Tomoyuki; Hisakane, Kakeru; Goto, Kōichi; Tsuboi, Masahiro

doi:10.1093/icvts/ivx400

Cited by 21 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tzouvelekis et al [ 12 ], recently reported a median survival of 14 months in patients with lung cancer and IPF from the time of lung cancer diagnosis. Sekihara et al [ 13 ], reported 5 year-overall survival of 40% in patients with lung cancer and ILD as opposed to 72% in those with lung cancer only without ILD. A meta-analysis done by Koo et al [ 7 ], showed lower survival rate in patients with lung cancer and CPFE as compared to those with lung cancer only and those with lung cancer and emphysema.…”

Section: Discussionmentioning

confidence: 99%

“…No significant difference was found in the survival rate amongst the patient groups of lung cancer and the 4 different categories of ILD according to the diagnosis of IPF in both unadjusted and adjusted cox regression model. Similarly, Sekihara et al reported no significant difference in the overall survival between patients with UIP pattern (41%) and those with non-UIP (possible UIP and inconsistent with UIP patterns) (41%) [ 13 ]. Maybe larger number of patients in future studies will be able to detect significant differences amongst the different types of ILD documented on CT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival analysis in lung cancer patients with interstitial lung disease

et al. 2021

View full text Add to dashboard Cite

Objective Lung cancer patients with interstitial lung disease (ILD) are prone for higher morbidity and mortality and their treatment is challenging. The purpose of this study is to investigate whether the survival of lung cancer patients is affected by the presence of ILD documented on CT. Materials and methods 146 patients with ILD at initial chest CT were retrospectively included in the study. 146 lung cancer controls without ILD were selected. Chest CTs were evaluated for the presence of pulmonary fibrosis which was classified in 4 categories. Presence and type of emphysema, extent of ILD and emphysema, location and histologic type of cancer, clinical staging and treatment were evaluated. Kaplan-Meier estimates and Cox regression models were used to assess survival probability and hazard of death of different groups. P value < 0.05 was considered significant. Results 5-year survival for the study group was 41% versus 48% for the control group (log-rank test p = 0.0092). No significant difference in survival rate was found between the four different categories of ILD (log-rank test, p = 0.195) and the different histologic types (log-rank test, p = 0.4005). A cox proportional hazard model was used including presence of ILD, clinical stage and age. The hazard of death among patients with ILD was 1.522 times that among patients without ILD (95%CI, p = 0.029). Conclusion Patients with lung cancer and CT evidence of ILD have a significantly shorter survival compared to patients with lung cancer only. Documenting the type and grading the severity of ILD in lung cancer patients will significantly contribute to their challenging management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Survival analysis in lung cancer patients with interstitial lung disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several case-control studies on Asian IPF patients, mostly unmatched, have been published. Authors of studies on surgically treated LC patients reported that IPF or ILD was associated with shorter survival and that the presence of either pattern was an independent prognostic factor [32][33][34][35]. For chemotherapy-treated patients, IPF or idiopathic ILD was an unfavorable factor for survival [15,36].…”

Section: Discussionmentioning

confidence: 99%

Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study

Gibiot

Monnet

Lévy

et al. 2020

JCM

View full text Add to dashboard Cite

Interstitial lung disease (ILD) seems to be associated with an increased risk of lung cancer (LC) and to have a poorer prognosis than LC without ILD. The frequency of ILD in an LC cohort and its prognosis implication need to be better elucidated. This retrospective, observational, cohort study evaluated the frequency of ILD among LC patients (LC–ILD) diagnosed over a 2-year period. LC–ILD patients’ characteristics were compared to those with LC without ILD (LC–noILD). Lastly, we conducted a case–control study within this cohort, matching three LC–noILDs to each LC–ILD patient, to evaluate the ILD impact on LC patients’ prognoses. Among 906 LC patients, 49 (5.4%) also had ILD. Comparing LC–ILD to LC–noILD patients, respectively, more were men (85.7% vs. 66.2%; p = 0.02); adenocarcinomas were less frequent (47.1% vs. 58.7%, p = 0.08); median [range] and overall survival was shorter: (9 [range: 0.1–39.4] vs. 17.5 [range: 0.8–50.4] months; p = 0.01). Multivariate analysis (hazard ratio [95% confidence interval]) retained two factors independently associated with LC risk of death: ILD (1.79 [1.22–2.62]; p = 0.003) and standard-of-care management (0.49 [0.33–0.72]; p < 0.001). Approximately 5% of patients with a new LC diagnosis had associated ILD. ILD was a major prognosis factor for LC and should be taken into consideration for LC management. Further studies are needed to determine the best therapeutic strategy for the LC–ILD population.

show abstract

“…Among previous studies that examined the survival of patients with IP after undergoing NSCLC resection [ 4 , 5 , 15 - 17 ], they examined the prognostic roles of clinicopathological factors, including Krebs von den Lungen-6 (KL-6), but not tumor markers. Therefore, in the present study, we examined the prognostic significance of serum tumor markers, and found that serum CEA level might serve as an efficient prognostic indicator after surgery in NSCLC with IP.…”

Section: Discussionmentioning

confidence: 99%

Serum Carcinoembryonic Antigen Level Predicts Cancer-Specific Outcomes of Resected Non-Small Cell Lung Cancer With Interstitial Pneumonia

et al. 2018

View full text Add to dashboard Cite

BackgroundIt has been well accepted that the prognosis of non-small cell lung cancer (NSCLC) patients with interstitial pneumonia (IP) is significantly poor. However, there are only a few studies that indicated the prognostic factors, especially tumor markers, among NSCLC patients with IP.MethodsForty-one NSCLC patients with IP who underwent surgery at our institution were included. Patients died of other diseases including postoperative acute exacerbation (AE) of IP were excluded. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model.ResultsThe 5-year cancer-specific survival of overall and stage I patients were 37.4% and 39.2%, respectively. The 5-year cancer-specific survival of patients with high serum carcinoembryonic antigen (CEA) level was 9.4%, while that with normal serum CEA level was 55.6%. However, serum cytokeratin-19 fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) levels were not associated with patients’ survival. Furthermore, serum CEA level was significantly associated with poorer cancer-specific survival in univariate and multivariate analyses.ConclusionsThis study demonstrated that serum CEA level might serve as an efficient prognostic indicator after surgery in NSCLC with IP.

show abstract

Long-term survival after complete resection of non-small-cell lung cancer in patients with interstitial lung disease

Abstract: The presence of ILD led to a much poorer survival after complete resection of non-small-cell lung cancer.

Cited by 21 publications

References 27 publications

Survival analysis in lung cancer patients with interstitial lung disease

Survival analysis in lung cancer patients with interstitial lung disease

Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study

Serum Carcinoembryonic Antigen Level Predicts Cancer-Specific Outcomes of Resected Non-Small Cell Lung Cancer With Interstitial Pneumonia

Contact Info

Product

Resources

About